Ganz P A, Shanley J D, Cherry J D
Cancer. 1978 Nov;42(5):2244-7. doi: 10.1002/1097-0142(197811)42:5<2244::aid-cncr2820420523>3.0.co;2-7.
Little information is available concerning influenza immunization in patients with malignancies receiving chemotherapy. A large number of ambulatory patients are receiving chemotherapy for metastatic disease as well as adjuvant chemotherapy for microscopic disease, and they should be considered at higher risk for complications should they contract influenza. Seventeen oncology patients and 15 control subjects were given bivalent influenza vaccine (A/NJ/76-A/Vic/75) and their serologic responses were monitored. Although their responses were less than controls, nearly 50% of the oncology patients had a greater than fourfold rise in antibody titer, suggesting that a humoral antibody response could be achieved in spite of their underlying disease and immunosuppressive chemotherapy. No adverse reactions or deterioration of patient's clinical status were noted with vaccination. We conclude that significant antibody titer responses can be achieved in this population of patients.
关于接受化疗的恶性肿瘤患者的流感免疫接种,目前可用信息较少。大量门诊患者正在接受转移性疾病的化疗以及微小疾病的辅助化疗,如果他们感染流感,应被视为发生并发症的风险更高。对17名肿瘤患者和15名对照受试者接种了二价流感疫苗(A/NJ/76-A/Vic/75),并监测了他们的血清学反应。尽管他们的反应低于对照组,但近50%的肿瘤患者抗体滴度有四倍以上的升高,这表明尽管他们有基础疾病和免疫抑制性化疗,仍可产生体液抗体反应。接种疫苗后未观察到不良反应或患者临床状况恶化。我们得出结论,在这类患者群体中可以实现显著的抗体滴度反应。